Oncternal Therapeutics
Stock Forecast, Prediction & Price Target
Oncternal Therapeutics Financial Estimates
Oncternal Therapeutics Revenue Estimates
Oncternal Therapeutics EBITDA Estimates
Oncternal Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $4.31M N/A | $1.49M -65.46% | $785K -47.31% | Avg: $700K Low: $600K High: $800K avg. -10.82% | Avg: $1M Low: $896.98K High: $1.10M avg. 42.85% | Avg: $1M Low: $896.98K High: $1.10M avg. 0% | Avg: $1M Low: $896.98K High: $1.10M avg. 0% |
Net Income
% change YoY
| $-31.3M N/A | $-43.39M -38.63% | $-39.47M 9.01% | Avg: $-46.37M Low: $-30.13M High: $-25.25M avg. -17.45% | Avg: $-56M Low: $-20.47M High: $-15.68M avg. -20.76% | Avg: $-19.96M Low: $-22.57M High: $-17.28M avg. 64.35% | Avg: $-14.02M Low: $-15.85M High: $-12.14M avg. 29.74% |
EBITDA
% change YoY
| $-31.36M N/A | $-44.94M -43.29% | $2.23M 104.97% | Avg: $-700K Low: $-800K High: $-600K avg. -131.31% | Avg: $-1M Low: $-1.10M High: $-896.98K avg. -42.85% | Avg: $-1M Low: $-1.10M High: $-896.98K avg. 0% | Avg: $-1M Low: $-1.10M High: $-896.98K avg. 0% |
EPS
% change YoY
| -$12.69 N/A | -$16.5 -30.02% | -$13.43 18.60% | Avg: -$9.42 Low: -$10.25 High: -$8.59 avg. 29.85% | Avg: -$6.16 Low: -$6.96 High: -$5.34 avg. 34.60% | Avg: -$6.79 Low: -$7.68 High: -$5.88 avg. -10.22% | Avg: -$4.77 Low: -$5.39 High: -$4.13 avg. 29.74% |
Operating Expenses
% change YoY
| $31.36M N/A | $44.94M 43.29% | $12.74M -71.64% | Avg: $4.68M Low: $4.01M High: $5.35M avg. -63.26% | Avg: $6.68M Low: $5.99M High: $7.36M avg. 42.85% | Avg: $6.68M Low: $5.99M High: $7.36M avg. 0% | Avg: $6.68M Low: $5.99M High: $7.36M avg. 0% |
FAQ
What is Oncternal Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 13.96% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -30.13M, average is -46.37M and high is -25.25M.
What is Oncternal Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8.00% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $600K, average is $700K and high is $800K.
What is Oncternal Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 20.99% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$10.25, average is -$9.42 and high is $-8.59.
What is the best performing analyst?
In the last twelve months analysts have been covering Oncternal Therapeutics stock. The most successful analyst is Raghuram Selvaraju.